Immunology & Autoimmune
Part of Biotech - Drug Development
 JNJ | Johnson & Johnson | $0.6t | $269.00 | +0.9% | 4.0M |
 ABBV | ABBVIE INC. | $464.4b | $286.50 | -0.1% | 2.1M |
 AMGN | Amgen Inc | $217.9b | $448.70 | +0.8% | 1.1M |
 BMY | Bristol-Myers Squibb Co. | $124.9b | $61.90 | -0.1% | 5.5M |
 REGN | Regeneron Pharmaceuticals Inc | $75.7b | $815.71 | +1.0% | 539.1K |
 ROIV | Roivant Sciences Ltd. Common Shares | $25.8b | $36.52 | +1.4% | 5.6M |
 IBRX | ImmunityBio, Inc. Common Stock | $10.9b | $8.59 | +10.5% | 9.4M |
 APGE | Apogee Therapeutics, Inc. Common Stock | $10.2b | $135.09 | 0.0% | N/A |
 PTGX | Protagonist Therapeutics, Inc | $9.1b | $141.13 | +0.5% | 373.2K |
 TGTX | TG Therapeutics, Inc. | $8.3b | $56.35 | +3.0% | 1.2M |
 SYRE | Spyre Therapeutics, Inc. Common Stock | $8.2b | $99.06 | +6.6% | 816.2K |
 IMVT | Immunovant, Inc. Common Stock | $6.9b | $28.86 | +2.4% | 885.6K |
 ORKA | Oruka Therapeutics, Inc. Common Stock | $5.6b | $96.38 | +6.1% | 1.1M |
 APLS | Apellis Pharmaceuticals, Inc. Common Stock | $5.2b | $41.04 | +0.0% | 68.6M |
 DNTH | Dianthus Therapeutics, Inc. Common Stock | $4.9b | $79.53 | +0.2% | 607.6K |
 ARQT | Arcutis Biotherapeutics, Inc. Common Stock | $3.2b | $32.01 | -0.5% | 1.5M |
 RCUS | Arcus Biosciences, Inc. | $3.1b | $18.15 | +2.1% | 1.8M |
 CLDX | Celldex Therapeutics, Inc | $2.5b | $30.14 | +2.2% | 587.9K |
 VERA | Vera Therapeutics, Inc. Class A Common Stock | $2.2b | $30.24 | +6.0% | 862.8K |
 ADMA | ADMA Biologics, Inc. | $2.2b | $11.19 | +1.1% | 1.7M |
 AUPH | Aurinia Pharmaceuticals Inc | $2.1b | $17.26 | +1.2% | 377.7K |
 BHVN | Biohaven Ltd. | $1.9b | $15.12 | +5.5% | 1.9M |
 XNCR | Xencor, Inc. | $1.8b | $29.94 | +2.7% | 1.6M |
 ZBIO | Zenas BioPharma, Inc. Common Stock | $1.8b | $27.31 | +0.0% | 289.2K |
 SEPN | Septerna, Inc. Common Stock | $1.8b | $44.13 | +6.6% | 185.5K |
 FBRX | Forte Biosciences, Inc. Common Stock | $1.6b | $76.98 | 0.0% | N/A |
 NKTR | Nektar Therapeutics | $1.5b | $38.00 | +1.4% | 361.2K |
 ANAB | AnaptysBio, Inc. Common Stock | $1.5b | $49.62 | +1.9% | 292.6K |
 TRAX | First Tracks Biotherapeutics, Inc. Ordinary Shares | $1.2b | $46.95 | +4.3% | 504.8K |
 CGEM | Cullinan Therapeutics, Inc. Common Stock | $1.0b | $15.15 | +2.2% | 315.9K |
 MLTX | MoonLake Immunotherapeutics Class A Ordinary Shares | $1.0b | $11.90 | +1.2% | 762.2K |
 CRVS | Corvus Pharmaceuticals, Inc. | $0.9b | $10.39 | +1.0% | 857.0K |
 JBIO | Jade Biosciences, Inc. Common Stock | $0.9b | $14.74 | +1.7% | 458.6K |
 ALMS | Alumis Inc. Common Stock | $0.9b | $6.58 | +1.8% | 2.8M |
 RIGL | Rigel Pharmaceuticals Inc. (New) | $0.9b | $50.30 | +1.4% | 90.8K |
 AVTX | Avalo Therapeutics, Inc. Common Stock | $0.8b | $6.68 | -0.2% | 2.3M |
 IMMX | Immix Biopharma, Inc. Common Stock | $0.8b | $8.05 | -0.1% | 986.6K |
 ODTX | Odyssey Therapeutics, Inc. Common Stock | $0.8b | $19.38 | +1.0% | 203.0K |
 ANNX | Annexon, Inc. Common Stock | $0.8b | $3.75 | +1.1% | 2.4M |
 STTK | Shattuck Labs, Inc. Common Stock | $0.7b | $5.77 | +4.3% | 505.8K |
 ACRS | Aclaris Therapeutics, Inc. | $0.6b | $3.67 | 0.0% | 7.0M |
 CLYM | Climb Bio, Inc. Common Stock | $0.6b | $9.85 | +8.6% | 3.7M |
 KYTX | Kyverna Therapeutics, Inc. Common Stock | $384.7m | $5.64 | +7.1% | 752.6K |
 ENTA | Enanta Pharmaceuticals, Inc | $377.5m | $12.19 | +1.3% | 263.2K |
 CABA | Cabaletta Bio, Inc. Common Stock | $339.1m | $1.43 | +7.4% | 6.0M |
 ZURA | Zura Bio Limited Class A Ordinary Shares | $322.0m | $4.14 | +20.2% | 4.6M |
 FATE | Fate Therapeutics, Inc. | $278.0m | $2.06 | +0.5% | 880.4K |
 IPSC | Century Therapeutics, Inc. Common Stock | $277.0m | $1.45 | +1.4% | 582.9K |
 UPB | Upstream Bio, Inc. Common Stock | $276.0m | $2.84 | +1.1% | 1.0M |
 SABS | SAB Biotherapeutics, Inc. Common Stock | $271.1m | $3.08 | +10.4% | 557.2K |